Biomarker Bulletin: October 10, 2011

Reading time: 2 – 3 minutes

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

• Recent Advances in Biomarker Discovery for Parkinson’s disease, a Satellite Symposium at the Society for Neuroscience Annual Meeting

  A satellite symposium, Recent Advances in Biomarker Discovery for Parkinson’s Disease, is being sponsored by Covance on November 13th, 2011 at the Society for Neuroscience Annual Meeting in Washington, D.C.

• NYAS Symposium: Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease

  The New York Academy of Sciences (NYAS) will be holding an afternoon event in January 2012 that focuses on biomarkers and brain imaging of presymptomatic Alzheimer’s disease.

• NIH to Support Clinical Trial Implementation or Biomarker Clinical Evaluation Studies

  Earlier this month, the National Institutes of Health announced that the National Institute of Dental and Craniofacial Research (NIDCR) Institute will support mission-relevant investigator-initiated Phase I, II, III or IV clinical trial cooperative agreement applications or biomarker evaluation studies that require prospective collection of clinical outcomes and clinical specimens.

• NIH to Fund Studies that Adapt Adult Biomarkers to Children

  The National Institutes of Health announced Thursday that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support studies that propose adapting adult biomarkers to children.

• CLC bio to Develop Bioinformatics Tools for Prostate Cancer Biomarker Project

  CLC bio is participating in a $4 million Danish collaboration focused on the identification and validation of biomarkers of prostate cancer risk and aggressiveness.